{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:49Z","timestamp":1753891249868,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000194","name":"Nova Scotia Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The role of type I and type III interferons (IFNs) in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) is still poorly understood. The objective of this study was to examine the hypothesis that IFN expression profiles in the peripheral blood differ between subsets of arthritic subjects. Multiple type I and type III IFNs were examined in patients with RA and JIA, as well as among subtypes of JIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment-na\u00efve RA and JIA patients were enrolled. Droplet digital PCR was used to measure the expression of type I, II, and III interferons in blood and synovial fluid leukocytes. Dendritic cell subsets were isolated from synovial fluid to examine IFN expression in each subset. Additionally, synovial mononuclear cells and JIA-derived fibroblast-like synoviocytes were stimulated with TNF, IFN\u03b3, and poly(I:C) to examine inducible IFN expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The predominant type I IFN gene expressed by blood leukocytes was <jats:italic>IFN\u03ba<\/jats:italic> and was significantly lower in RA than JIA and controls. Oligoarticular and psoriatic JIA subgroups showed higher <jats:italic>IFN\u03ba<\/jats:italic> expression compared to polyarticular JIA and RA. JIA synovial fluid leukocytes expressed abundant <jats:italic>IFN\u03b3<\/jats:italic> and type III IFNs (<jats:italic>IFN\u03bb1, IFN\u03bb3<\/jats:italic>), with distinct dendritic cell subset contributions. JIA fibroblast-like synoviocytes produced IFN\u03b2, IFN\u03bb1, and IFN\u03bb2 mRNA upon poly(I:C) stimulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study revealed differences in IFN expression patterns in RA and JIA, with notable differences between JIA subtypes. The expression levels of <jats:italic>IFN\u03ba, IFN\u03b3<\/jats:italic>, <jats:italic>IFN\u03bb1 and IFN\u03bb3<\/jats:italic> in JIA suggest specific roles in disease pathology, influenced by disease subtype and joint microenvironment. This study contributes to understanding IFN-mediated mechanisms in arthritis, potentially guiding targeted therapeutic strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1466397","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:46:41Z","timestamp":1727455601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential type I and type III interferon expression profiles in rheumatoid and juvenile idiopathic arthritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Anik\u00f3 E.","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Slauenwhite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Hanly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Be\u00e1ta","family":"D\u00e9rfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Issekutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101519","DOI":"10.1016\/j.smim.2021.101519","article-title":"Cellular and molecular diversity in rheumatoid arthritis","volume":"58","author":"Rivellese","year":"2022","journal-title":"Semin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/25785826.2020.1751908","article-title":"New insights into IFN-\u03b3 in rheumatoid arthritis: role in the era of JAK inhibitors","volume":"43","author":"Kato","year":"2020","journal-title":"Immunological Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"Lopez de Padilla","year":"2016","journal-title":"Gene"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e002525","DOI":"10.1136\/rmdopen-2022-002525","article-title":"Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature","volume":"8","author":"Karonitsch","year":"2022","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9631510","article-title":"Interleukin-29 enhances synovial inflammation and cartilage degradation in osteoarthritis","volume":"2016","author":"Xu","year":"2016","journal-title":"Mediat Inflamm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ni.3821","article-title":"IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function","volume":"18","author":"Broggi","year":"2017","journal-title":"Nat Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.molmed.2017.08.002","article-title":"Genome engineering for personalized arthritis therapeutics","volume":"23","author":"Adkar","year":"2017","journal-title":"Trends Mol Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.coi.2018.10.007","article-title":"Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control","volume":"56","author":"Andreakos","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1620\/tjem.241.89","article-title":"Elevated serum levels of interleukin-29 are associated with disease activity in rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies","volume":"241","author":"Chang","year":"2017","journal-title":"Tohoku J Exp Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1136\/ard.2005.040477","article-title":"Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/rheumatology\/kel346","article-title":"Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue","volume":"46","author":"Gattorno","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref21","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0231664","DOI":"10.1371\/journal.pone.0231664","article-title":"Highly efficient serum-free manipulation of miRNA in human NK cells without loss of viability or phenotypic alterations is accomplished with TransIT-TKO","volume":"15","author":"Hargreaves","year":"2020","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","article-title":"The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fimmu.2017.00285","article-title":"Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production","volume":"8","author":"Castaneda-Delgado","year":"2017","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/ijms22084190","article-title":"Type I interferon production of Plasmacytoid dendritic cells under control","volume":"22","author":"Bencze","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.coviro.2011.10.026","article-title":"Type I interferons: diversity of sources, production pathways and effects on immune responses","volume":"1","author":"Swiecki","year":"2011","journal-title":"Curr Opin Virol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"154605","DOI":"10.1016\/j.cyto.2018.11.022","article-title":"The influence of interferon on healthy and diseased skin","volume":"132","author":"Hile","year":"2020","journal-title":"Cytokine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5084682","article-title":"Interferon kappa is important for keratinocyte host Defense against herpes simplex Virus-1","volume":"2020","author":"Li","year":"2020","journal-title":"J Immunol Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"39765","DOI":"10.1074\/jbc.M102502200","article-title":"Interferon-kappa, a novel type I interferon expressed in human keratinocytes","volume":"276","author":"LaFleur","year":"2001","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/CCID.S218243","article-title":"Interferon kappa is up-regulated in psoriasis and it up-regulates psoriasis-associated cytokines in vivo","volume":"12","author":"Li","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.4049\/jimmunol.169.9.4822","article-title":"Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system","volume":"169","author":"Nardelli","year":"2002","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","article-title":"Biological classification of childhood arthritis: roadmap to a molecular nomenclature","volume":"17","author":"Nigrovic","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1615\/CritRevImmunol.2013005868","article-title":"Functions of TGF-beta-exposed plasmacytoid dendritic cells","volume":"32","author":"Saas","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-beta\/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta\/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"R228","DOI":"10.1186\/ar4067","article-title":"Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis","volume":"14","author":"Wang","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1172\/jci.insight.95228","article-title":"Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis. JCI","volume":"3","author":"Canavan","year":"2018","journal-title":"Insight"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1084\/jem.20140995","article-title":"IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production","volume":"212","author":"Blazek","year":"2015","journal-title":"J Exp Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3389\/fimmu.2019.01395","article-title":"Regulation of immune responses and chronic inflammation by fibroblast-like Synoviocytes","volume":"10","author":"Yoshitomi","year":"2019","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I interferons in the pathogenesis and treatment of autoimmune diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1466397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:46:47Z","timestamp":1727455607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1466397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":42,"alternative-id":["10.3389\/fmed.2024.1466397"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1466397","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"article-number":"1466397"}}